Life Science Investing Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
Life Science Investing Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
Life Science Investing Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Life Science Investing Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
Life Science Investing Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology Congress 2025
pharmaceutical investing Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs
Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas
pharmaceutical investing Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006
pharmaceutical investing Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Silver Dollar Discovers New Mineralized Zone at the Nora Silver-Gold Project and Receives Drill Permit
Terra Clean Closes the Acquisition of the Past Producing Uranium Claims in San Rafael Swell, Utah, United States
CHARBONE Confirms Construction Schedule on Track at Sorel-Tracy and Announces the Imminent Start of Equipment Installation Phase
